Product logins

Find logins to all Clarivate products below.


Chronic Kidney Disease | Treatment Algorithms: Claims Data Analysis | US | 2023

Chronic kidney disease (CKD) is caused by structural or functional abnormalities in the kidney that impair its ability to filter blood. The CKD drug market primarily comprises antihypertensive agents and SGLT-2 inhibitors, which are intended to delay the disease’s progression. RAAS inhibitors are the standard of care for CKD, but newer agents from the SGLT-2 inhibitor and MRA classes could transform the treatment algorithm. In 2021, AstraZeneca’s Farxiga (dapagliflozin) became the first SGLT-2 inhibitor to demonstrate a renoprotective effect in a dedicated CKD outcomes trial and receive approval from the FDA for the treatment of CKD irrespective of the presence of diabetes. Also in 2021, Bayer’s MRA Kerendia (finerenone) received approval for CKD after it demonstrated renoprotective and cardioprotective benefits in type 2 diabetes patients with CKD in the FIDELIO-DKD and FIGARO-DKD trials. In 2022, Eli Lilly’s Jardiance (empagliflozin) demonstrated renoprotective benefits in the EMPA-KIDNEY trial.

Questions answered

  • What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CKD patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CKD patients?
  • How have Jardiance, Farxiga, and Kerendia been integrated into the treatment algorithm, and what are their sources of business?
  • What percentage of CKD patients receive drug therapy within 365 days of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within 365 days of diagnosis?
  • What percentage of CKD patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
  • What are the product-level compliance and persistency rates among drug-treated patients?

Markets covered: United States.

Key companies: AstraZeneca, Eli Lilly, Boehringer Ingelheim.

Key drugs: Jardiance, Farxiga, Invokana, Kerendia.

Product description

Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.

Solution enhancement

The accompanying interactive dashboard provides novel delivery of data with interactive visuals, easier navigation, expanded analyses, and optional quarterly data refreshes.

Related Market Assessment Reports

Report
Primary Biliary Cholangitis – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Primary biliary cholangitis (PBC) is a rare autoimmune liver disease, characterized by inflammation and progressive damage leading to destruction of interlobular bile ducts, followed by cholestasis…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Adult Asthma (US)
Two types of pharmacotherapies are used to treat adult asthma: rescue drugs and maintenance therapies. Rescue drugs are inhaled therapies that treat the acute symptoms of asthma via bronchodilation…
Report
Asthma – Current Treatment – Treatment Algorithms: Claims Data Analysis – Pediatric Asthma (US)
Pediatric asthma is treated using two types of pharmacotherapies: rescue therapy for acute symptoms via bronchodilation (e.g., a SABA such as Teva’s ProAir HFA) and maintenance therapy to prevent…
Report
Acute Coronary Syndrome – Unmet Need – Unmet Need – Acute Coronary Syndrome: Secondary Prevention, on Top of Statin Treatment (US/EU)
This report covers the 12-month post-hospital management of secondary prevention in ACS patients. Reducing cardiovascular (CV) residual risk and achieving guideline-recommended LDL-C targets…
Report
Beta Thalassemia – Landscape & Forecast – Niche & Rare Disease Landscape & Forecast (US/EU5)
Beta thalassemia (BT) is a rare genetic disorder characterized by the reduced production of hemoglobin. BT minor is caused by a mutation in one hemoglobin beta (HBB) gene, and transfusion-dependent…